Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2490367 | Medical Hypotheses | 2010 | 4 Pages |
Abstract
SummaryThere is a rising interest towards the old drug, nicotinic acid (niacin, vitamin B3), because at pharmacological concentrations it has a beneficial effect on HDL cholesterol. Its use, however, was limited due to its adverse effect, flushing. When the mechanism of flushing was solved, a combination of niacin and DP1 receptor antagonist or prostaglandin inhibitor is used, there has been a comeback of niacin with extensive clinical trials. This paper argues that the new strategy with niacin for the prevention of atherosclerosis should be re-evaluated, because vasodilatation of the peripheral vessels might be crucially important in the early primary prevention according to our “vasa vasorum hypoxia” hypothesis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
P. Tuohimaa, M. Järvilehto,